<DOC>
	<DOCNO>NCT02588443</DOCNO>
	<brief_summary>The main purpose study learn add investigational drug RO7009789 ( anti-CD40 ) nab-paclitaxel gemcitabine surgery surgery safe , feasible , beneficial patient pancreatic cancer . This study also intend look blood tissue sample help doctor well understand role immune system fight cancer .</brief_summary>
	<brief_title>Study Neo-adjuvant RO7009789 Alone Neo-adjuvant RO7009789 Plus Nab-Paclitaxel Gemcitabine Followed Adjuvant RO7009789 Plus Nab-Paclitaxel Gemcitabine Patients With Newly Diagnosed Resectable Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histological documentation primary adenocarcinoma pancreas Surgically eligible tumor resection curative intent Age ≥18 year ECOG PS 0 1 Adequate bone marrow function ( ANC ≥1,500 ; Hgb &gt; 9 ; Plt &gt; 100 ) Adequate renal function ( Cr &lt; 1.5 ULN ) Total bilirubin ≤1.5 x ULN ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN ( value post biliary stenting allow eligibility ) . Signed , write informed consent Non ductal adenocarcinoma , neuroendocrine neoplasm , cystic tumor pancreas cystadenomas , cystadenocarcinomas solid pseudopapillary neoplasm . In addition , adenocarcinomas arise duodenum , distal bile duct , ampulla also exclude . Patients M1 disease history M1 disease . Patients type recurrent pancreatic adenocarcinoma Prior therapy chemotherapy radiation therapy antitumor experimental therapy pancreatic cancer Previous treatment compound target CD40 Concurrent treatment anticancer agent outside protocol Prior allogeneic bone marrow transplant History autoimmune disorder , include type 1 diabetes mellitus , pemphigus vulgaris , systemic mastocytosis , systemic lupus erythromatosis , dermatomyositis/polymyositis , rheumatoid arthritis , systemic sclerosis , Sjörgen 's syndrome , vasculitis/arteritis , Behcet 's syndrome , autoimmune thyroiditis , multiple sclerosis , uveitis , . ( Vitiligo allow ) History ( within previous year ) stroke transient ischemic attack , unstable angina , myocardial infarction , congestive heart failure History deep venous thrombosis migratory thrombophlebitis ( Trousseau ) ; Hereditary acquire coagulopathies ( e.g. , hemophilia , von Willebrand disease , cancerassociated DIC ) Prior allergic reaction attribute monoclonal antibody Concurrent plan concurrent treatment systemic high dose ( immunosuppressive ) corticosteroid treatment systemic corticosteroid within 4 week baseline Treatment another therapeutic clinical trial within 4 week enrollment trial Concurrent plan concurrent treatment anticoagulant Coumadin heparin , except maintain patency indwell catheter Ongoing active infection ; treatment systemic antibiotic antifungal ongoing recurrent infection ( topical use antibiotic antifungal allow ) Pregnancy breastfeed female patient must surgically sterile , postmenopausal , must agree use effective contraception period therapy 90 day follow last dose RO7009789 . All female patient reproductive potential must negative pregnancy test prior enrollment . Women men reproductive potential may participate unless agree use effective contraceptive method . Female patient become pregnant participate research study 90 day follow therapy . Male patient father child research study 90 day follow therapy . Other uncontrolled , concurrent illness would preclude study participation ; , psychiatric illness social challenge would entail unreasonable risk preclude inform consent compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>